SG11202102317PA - Methods of treating immunotherapy-related toxicity using a gm-csf antagonist - Google Patents
Methods of treating immunotherapy-related toxicity using a gm-csf antagonistInfo
- Publication number
- SG11202102317PA SG11202102317PA SG11202102317PA SG11202102317PA SG11202102317PA SG 11202102317P A SG11202102317P A SG 11202102317PA SG 11202102317P A SG11202102317P A SG 11202102317PA SG 11202102317P A SG11202102317P A SG 11202102317PA SG 11202102317P A SG11202102317P A SG 11202102317PA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- related toxicity
- csf antagonist
- immunotherapy
- treating
- Prior art date
Links
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 title 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 230000001988 toxicity Effects 0.000 title 1
- 231100000419 toxicity Toxicity 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001112—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862729043P | 2018-09-10 | 2018-09-10 | |
US16/149,346 US10870703B2 (en) | 2017-10-02 | 2018-10-02 | Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist |
PCT/US2018/053933 WO2019070680A2 (en) | 2017-10-02 | 2018-10-02 | METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING GM-CSF ANTAGONIST |
US16/204,220 US10899831B2 (en) | 2017-10-02 | 2018-11-29 | Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity |
US16/248,762 US10927168B2 (en) | 2017-10-02 | 2019-01-15 | Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab |
US16/283,694 US11130805B2 (en) | 2017-10-02 | 2019-02-22 | Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist |
PCT/US2019/050494 WO2020055932A2 (en) | 2018-09-10 | 2019-09-10 | Methods of treating immunotherapy-related toxicity using a gm-csf antagonist |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202102317PA true SG11202102317PA (en) | 2021-04-29 |
Family
ID=69778357
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202102317PA SG11202102317PA (en) | 2018-09-10 | 2019-09-10 | Methods of treating immunotherapy-related toxicity using a gm-csf antagonist |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP3849572A4 (de) |
JP (1) | JP2022517461A (de) |
KR (1) | KR20210075090A (de) |
CN (1) | CN113164520A (de) |
AU (1) | AU2019340662A1 (de) |
BR (1) | BR112021004489A2 (de) |
CA (1) | CA3111804A1 (de) |
IL (1) | IL281243A (de) |
MX (1) | MX2021002856A (de) |
SG (1) | SG11202102317PA (de) |
WO (1) | WO2020055932A2 (de) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020092850A1 (en) * | 2018-10-31 | 2020-05-07 | Humanigen, Inc. | Materials and methods for treating cancer |
EP3976080A1 (de) * | 2019-06-03 | 2022-04-06 | Kiniksa Pharmaceuticals, Ltd. | Behandlung von krebs mit gm-csf-antagonisten |
WO2021204649A1 (en) * | 2020-04-06 | 2021-10-14 | Glaxosmithkline Intellectual Property Development Limited | Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome |
CN113402620B (zh) * | 2021-07-30 | 2021-12-10 | 中山大学 | 细胞因子联合嵌合抗原受体的融合蛋白及其应用 |
WO2023138499A1 (zh) * | 2022-01-20 | 2023-07-27 | 舒泰神(北京)生物制药股份有限公司 | 一种特异性地识别粒细胞-巨噬细胞集落刺激因子受体的抗体制剂及其应用 |
CN114606237A (zh) * | 2022-05-11 | 2022-06-10 | 上海优替济生生物医药有限公司 | Gm-csf抑制剂及其用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8398972B2 (en) * | 2006-11-21 | 2013-03-19 | Kalobios Pharmaceuticals, Inc. | Methods of treating dementia using a GM-CSF antagonist |
KR101824512B1 (ko) * | 2008-04-28 | 2018-02-02 | 휴머니건, 아이엔씨. | 과립구-대식세포 콜로니 자극 인자에 대한 항체 |
HUE061555T2 (hu) * | 2012-07-13 | 2023-07-28 | Univ Pennsylvania | CAR-ok tumorellenes hatásának toxicitáskezelése |
US20160024200A1 (en) * | 2013-03-14 | 2016-01-28 | John Schrader | Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof |
WO2015066262A1 (en) * | 2013-11-04 | 2015-05-07 | Trustees Of Dartmouth College | Methods for preventing toxicity of adoptive cell therapy |
CA3040914A1 (en) * | 2016-11-03 | 2018-05-24 | Juno Therapeutics, Inc. | Combination therapy of a cell based therapy and a microglia inhibitor |
US10899831B2 (en) * | 2017-10-02 | 2021-01-26 | Humanigen, Inc. | Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity |
CA3078349A1 (en) * | 2017-10-02 | 2019-04-11 | Humanigen, Inc. | Methods of treating immunotherapy-related toxicity using a gm-csf antagonist |
CA3101991A1 (en) * | 2018-06-01 | 2019-12-05 | Mayo Foundation For Medical Education And Research | Materials and methods for treating cancer |
-
2019
- 2019-09-10 BR BR112021004489-2A patent/BR112021004489A2/pt not_active Application Discontinuation
- 2019-09-10 SG SG11202102317PA patent/SG11202102317PA/en unknown
- 2019-09-10 JP JP2021512883A patent/JP2022517461A/ja active Pending
- 2019-09-10 AU AU2019340662A patent/AU2019340662A1/en active Pending
- 2019-09-10 MX MX2021002856A patent/MX2021002856A/es unknown
- 2019-09-10 CN CN201980073595.4A patent/CN113164520A/zh active Pending
- 2019-09-10 WO PCT/US2019/050494 patent/WO2020055932A2/en unknown
- 2019-09-10 KR KR1020217010585A patent/KR20210075090A/ko unknown
- 2019-09-10 EP EP19860890.3A patent/EP3849572A4/de active Pending
- 2019-09-10 CA CA3111804A patent/CA3111804A1/en active Pending
-
2021
- 2021-03-03 IL IL281243A patent/IL281243A/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL281243A (en) | 2021-04-29 |
EP3849572A2 (de) | 2021-07-21 |
MX2021002856A (es) | 2021-05-28 |
KR20210075090A (ko) | 2021-06-22 |
EP3849572A4 (de) | 2022-07-13 |
WO2020055932A2 (en) | 2020-03-19 |
AU2019340662A1 (en) | 2021-05-06 |
CN113164520A (zh) | 2021-07-23 |
BR112021004489A2 (pt) | 2021-07-20 |
CA3111804A1 (en) | 2020-03-19 |
WO2020055932A9 (en) | 2020-07-09 |
WO2020055932A3 (en) | 2020-05-22 |
JP2022517461A (ja) | 2022-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202003096UA (en) | Methods of treating immunotherapy-related toxicity using a gm-csf antagonist | |
IL283639A (en) | kif18a inhibitors | |
IL281243A (en) | Methods for the treatment of toxicity associated with immunotherapy with the help of a GM-CSF antagonist | |
ZA201906817B (en) | Methods of treatment using a jak inhibitor compound | |
IL276269A (en) | Aminopyrrolotriazines as kinase inhibitors | |
EP3894768C0 (de) | Verfahren zur kryohärtung | |
IL276592A (en) | History of Subtirum | |
GB201804627D0 (en) | A method of communicating | |
ZA201904460B (en) | Inhibitors of nhe-mediated antiport | |
IL276013A (en) | pi4kiiibeta inhibitors | |
IL287876A (en) | Jak inhibitors | |
ZA202101887B (en) | Dp antagonist | |
GB201907882D0 (en) | Methods | |
GB201810746D0 (en) | Use of sclerostin antagonist | |
IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | |
IL281599A (en) | TYK2 kinase inhibitors | |
IL279419A (en) | CCL5 inhibitors | |
GB201906705D0 (en) | Methods | |
IL290381A (en) | Jak inhibitors | |
IL277578A (en) | New salt forms of URAT-1 inhibitors | |
GB201907157D0 (en) | Methods | |
GB201903909D0 (en) | Methods | |
GB201901817D0 (en) | Methods | |
GB201807845D0 (en) | Kinase Inhibitors | |
SG11202101817UA (en) | Methods of inhibition |